沙格列汀联合胰岛素治疗对新诊断2型糖尿病患者分泌型磷脂酶A2水平的影响  

Effects of insulin combined with saxagliptin on levels of secreted phospholipase A2 in patients with newly diagnosed type 2 diabetes mellitus

作　　者：肖婧[1] 徐婉 XIAO Jing;XU Wan(Department of Endocrology,Central Hospital of Xiangyang,Xiangyang Hubei 441021)

机构地区：[1]湖北省襄阳市中心医院内分泌科,湖北襄阳441021

出　　处：《中南药学》2018年第8期1143-1146,共4页Central South Pharmacy

基　　金：2015-2016年度湖北省卫生计生青年人才项目:脂肪因子CTRP3通过AKT信号通路调控2型糖尿病胰岛β细胞功能的效应及机制(编号:WJ2015Q018)

摘　　要：目的探讨沙格列汀联合胰岛素治疗对新诊断2型糖尿病(T2DM)患者分泌型磷脂酶A2(s PLA2水平的影响。方法选取2013年6月至2017年5月期间在本院内分泌科就诊的新诊断T2DM患者128例作为研究对象,按照入院顺序,根据随机抽签原则分为观察组与对照组各64例,对照组给予胰岛素治疗,观察组在对照组治疗的基础上给予沙格列汀治疗,两组都治疗观察3个月。结果与治疗前相比,观察组与对照组治疗后空腹血糖明显降低(P<0.05),餐后2 h血糖值明显降低(P<0.05);观察组治疗期间的腹泻、恶心、低血糖等不良反应发生率为9.4%,对照组为6.3%,两组对比差异无统计学意义(P>0.05)。与治疗前对比,治疗后两组的Homa-IR明显下降,FINs明显上升(P<0.05);与对照组对比,治疗后观察组的Homa-IR、FINs差异明显(P<0.05)。观察组与对照组治疗后的s PLA2分别为(55.20±11.92)U·mL^(-1)和(64.22±12.84)U·mL^(-1),都明显低于治疗前的(85.22±10.47)U·mL^(-1)和(86.20±13.82)U·mL^(-1)(P<0.05),观察组也明显低于对照组(P<0.05)。结论沙格列汀联合胰岛素治疗新诊断T2DM患者有利于降低s PLA2的表达,能更有效地发挥调节机体胰岛功能,从而促进血糖的降低,安全性也比较好,有很好的应用价值。Objective To determine the effects of insulin combined with saxagliptin on levels of secreted phospholipase A2 （sPLA2） in patients with newly diagnosed type 2 diabetes mellitus （T2DM）. Methods From June 2013 to May 2017, 128 newly diagnosed T2DM patients treated in the Department of Endocrinology of our hospital were selected as the research subject. The patients were divided into an observation group and a control group with 64 patients in each group accorded to the order of admission. The control group was given insulin therapy, the observation group was given insulin combined with saxagliptin, and both groups were treated for 3 months. Results The fasting blood glucose and postprandial 2 h blood glucose in the observation group and the control group after the treatment were significantly lower than those before the treatment （P〈 0.05）. The incidence of adverse reactions such as diarrhea, nausea and hypoglycemia in the observation group and the control group were 9.4% and 6.3% respectively, with no significant difference between the two groups （P 〉 0.05）. After the treatment, Homa-IR of the two groups was decreased and FINs were increased （P 〈 0.05）, with significant difference in both group （P 〈 0.05）. The sPLA2 in the observation group and in the control group after the treatment was （55.20± 11.92） U ·mL - 1, and （64.22± 12.84） U · mL - 1, significantly lower than before the treatment [（85.22± 10.47） U · mL - 1 and （86.20± 13.82） U ·mL - 1] （p 〈 0.05）, with the observation group significantly lower than the control group （P 〈 0.05）. Conclusion The insulin combined with saxagliptin for newly diagnosed T2DM patients can reduce the expression of sPLA2, regulate the islet function safely with good application value.

关 键 词：沙格列汀 胰岛素 2型糖尿病 分泌型磷脂酶A2 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]